PTSD Clinical Trial Monitor — MDMA-Assisted Therapy, Stellate Ganglion Block & Novel Treatment Alerts 2026

The PTSD trial landscape in 2026 — disruption, setback, and resilience

Post-traumatic stress disorder affects approximately 13 million Americans in any given year and is the most prevalent service-connected mental health condition among U.S. veterans. Despite its prevalence and the enormous burden of suffering it causes — in veterans, first responders, survivors of sexual assault and childhood trauma, and many others — PTSD pharmacotherapy has not advanced meaningfully in over two decades. The two FDA-approved medications for PTSD are sertraline and paroxetine, both SSRI antidepressants approved in 1999 and 2001. Both achieve response rates of 40–60% in clinical trials, but remission rates (full resolution of PTSD symptoms) are far lower — typically 20–30% — meaning the majority of people taking these drugs remain significantly symptomatic.

Against this backdrop, the PTSD clinical trial space in 2025-2026 is defined by a moment of high scientific excitement and significant regulatory uncertainty. MDMA-assisted psychotherapy — the most scientifically compelling PTSD treatment advance in decades — received a Complete Response Letter (CRL) from FDA in August 2024, rejecting the Lykos Therapeutics NDA despite Phase 3 MAPP trial data showing remission rates nearly double those of existing treatments. The FDA's concerns centered on functional unblinding (participants knew whether they received MDMA or placebo), the adequacy of the blinded therapy component as a control condition, and the Risk Evaluation and Mitigation Strategy (REMS) requirements for a controlled substance with abuse potential in a therapeutic context. This was a setback for the field, but not a death sentence — Lykos is engaging with FDA on a remediation path, and the broader psychedelic-assisted therapy research agenda continues across psilocybin, ketamine, and other modalities.

Simultaneously, a different kind of innovation is gaining traction in the VA system: the stellate ganglion block (SGB), a cervical sympathetic nerve block with a surprisingly strong signal in PTSD. Reset Medical and Wellness and academic VA collaborators have been running trials on bilateral cervical sympathetic blocks, which FDA granted Breakthrough Device Designation to in 2021 — a designation that was subsequently revoked (per available information) as the evidence base was reassessed but which continues to generate active trial registrations. For PTSD researchers, VA/DoD funders, and organizations like Cohen Veterans Bioscience and MAPS, monitoring these parallel tracks simultaneously requires a monitoring system that spans pharmacotherapy, device interventions, and psychedelic-assisted therapy in a single daily alert.

Key mechanisms, interventions, and programs in 2026 PTSD trials

• MDMA-assisted therapy (Lykos Therapeutics): MDMA (3,4-methylenedioxymethamphetamine) acts as a serotonin, dopamine, and norepinephrine releasing agent, with large acute increases in oxytocin and prolactin that facilitate trust and emotional openness during psychotherapy sessions. The MAPP Phase 3 trials showed ~67% of participants no longer met PTSD diagnostic criteria after three MDMA-assisted therapy sessions — compared to ~32% in the placebo-plus-therapy arm. Despite the FDA CRL in 2024, Lykos is continuing Phase 3 investigations under a revised protocol addressing functional unblinding and trial design concerns. Monitoring for new Lykos or investigator-initiated MDMA PTSD trial registrations is a top priority for any organization tracking the psychedelic-assisted therapy space.
• Stellate ganglion block (SGB) / bilateral cervical sympathetic block: The stellate ganglion is a sympathetic nerve ganglion in the cervical region; injecting local anesthetic around it temporarily interrupts sympathetic outflow from the head, neck, and upper extremities. The hypothesis for PTSD is that trauma causes excess nerve growth factor (NGF)-driven sprouting in the stellate ganglion, creating a hyperactive sympathetic state that maintains the hyperarousal symptoms of PTSD. A cervical block reverses this. Reset Medical and Wellness is among the principal sponsors running SGB trials in veterans. The signal is particularly interesting for combat PTSD because the intervention is a single or bilateral procedure (not a daily medication), and early results in military populations showed statistically significant reductions on PTSD Checklist scores. The mechanism is contested but the clinical signal has generated enough interest to warrant continued Phase 2/3 investigation.
• Prolonged Exposure (PE) and Cognitive Processing Therapy (CPT) combinations: These remain the gold-standard psychotherapy approaches for PTSD, but engagement and completion rates are a significant limitation — many patients drop out before completing the full PE protocol due to the distress involved in trauma reprocessing. Trials combining PE or CPT with pharmacological augmentation (D-cycloserine for fear extinction enhancement, propranolol for fear memory reconsolidation, MDMA) or with technological augmentation (virtual reality, app-based between-session support) are active in VA and academic settings.
• MDMA combined with EMDR: EMDR (Eye Movement Desensitization and Reprocessing) is an established PTSD therapy. A Center hospitalier (France) trial is investigating MDMA-augmented EMDR, combining the neurochemical openness of MDMA with the specific trauma reprocessing technique of EMDR. This represents a different combination approach than the manualized MDMA-AT protocol used in the MAPP trials.
• Ketamine for acute PTSD: IV ketamine (NMDA receptor antagonist) has demonstrated rapid antidepressant effects and is approved for treatment-resistant depression via the esketamine intranasal route (Spravato). In PTSD, ketamine's rapid reduction of intrusive symptoms and potential to disrupt fear memory reconsolidation are the primary therapeutic rationale. Phase 2 trials in acute PTSD (within 3 months of trauma exposure) and chronic treatment-resistant PTSD are active at several VA and academic sites. If ketamine can be shown to reduce PTSD symptom consolidation in the acute post-trauma window, the implications for military and disaster medicine are significant.
• Cannabis and CBD approaches: Several state-funded and advocacy-funded observational and randomized trials in the U.S. and Canada are investigating cannabis use in veterans with PTSD. The VA has historically been restricted from studying cannabis, but NIH and academic center studies are filling this gap. CBD-specific trials (avoiding THC's psychoactive effects) are also in Phase 1/2. Results are mixed and methodologically heterogeneous, but the patient advocacy interest is high enough that these trials remain important to monitor.
• Psilocybin in moral injury and combat PTSD: Moral injury — the psychological damage from perpetrating, witnessing, or failing to prevent acts that violate moral beliefs — is distinct from classic fear-based PTSD but equally debilitating in veterans. Several Phase 1/2 trials are investigating psilocybin-assisted therapy specifically for moral injury in combat veterans and for treatment-resistant PTSD more broadly. These trials are largely investigator-initiated and VA/DoD-funded, not commercial Lykos/industry programs. They represent the leading edge of what comes after MDMA in the psychedelic-assisted therapy pipeline.
• Propranolol for fear memory reconsolidation: Consolidated fear memories are not static — each time they are retrieved, they briefly re-enter a labile state before being re-consolidated. Propranolol (a beta-blocker) given during this reconsolidation window can blunt the emotional charge of a traumatic memory without erasing its content. Phase 2 trials in chronic PTSD are testing propranolol-assisted trauma recall sessions as a way to reduce the fearfulness of traumatic memories. Low-cost, widely available, and mechanistically elegant — but evidence is still Phase 2.
• Family Involvement in Treatment for PTSD (FIT-PTSD) and integrated programs: VA-funded trials on integrating family members into PTSD treatment (FIT-PTSD protocol) and integrated PTSD plus weight management programs (addressing the comorbid metabolic burden in veteran populations) represent the health services research dimension of the PTSD trial portfolio — less about new molecules and more about implementation of effective care.

What DataLookout monitors for PTSD

DataLookout pulls from the ClinicalTrials.gov API daily. For a PTSD monitoring profile, you can configure:

• Condition keywords: "post-traumatic stress disorder", "PTSD", "combat PTSD", "sexual assault PTSD", "moral injury", "trauma-related disorder", "acute stress disorder"
• Intervention keywords: "MDMA", "psilocybin", "ketamine", "stellate ganglion block", "cervical sympathetic block", "propranolol", "prolonged exposure", "cognitive processing therapy", "EMDR", "cannabis", "CBD"
• Sponsor filter: VA/DoD (enter "Veterans Affairs" or "Department of Defense"), academic, or industry-sponsored depending on your monitoring goal
• Phase filter: Phase 2/3 for near-term impact programs, all phases for comprehensive pipeline coverage
• Status filter: Recruiting only, or all active including not yet recruiting and active/not recruiting follow-up phases

Deep dive: The MDMA setback and what comes next for psychedelic PTSD treatment

The FDA's August 2024 Complete Response Letter for Lykos Therapeutics' MDMA-assisted therapy NDA was a significant setback for the psychedelic-assisted therapy field — but it is important to understand precisely what the FDA rejected and what it did not, because the distinction determines what the next three to five years of PTSD trial activity will look like.

The FDA did not reject MDMA-AT on efficacy grounds. The clinical data — from the MAPP1 and MAPP2 Phase 3 trials — showed clinically and statistically significant reductions in PTSD severity and high remission rates compared to placebo-augmented therapy. This signal is not in dispute. What the FDA rejected was the adequacy of the clinical trial design and the proposed risk management framework. The specific concerns documented in the CRL and in the advisory committee proceedings include: functional unblinding (both participants and therapists could reliably identify who received MDMA, which could inflate placebo effect estimates and introduce rater bias in the therapy assessment); the adequacy of the manualized therapy protocol as a control condition; insufficient characterization of MDMA's abuse potential in the therapeutic context; and questions about the generalizability of the highly trained, experienced therapist dyads used in the trials to real-world implementation.

These are scientifically legitimate regulatory concerns, and addressing them will require protocol modifications that go beyond simply rerunning the same trial. The functional unblinding problem is inherently difficult to solve with an active psychedelic — participants experiencing the unmistakable subjective effects of MDMA will almost always know they received the drug. Possible solutions include: use of an active comparator (low-dose MDMA or a drug with mild psychoactive effects as placebo); rater blinding procedures where the primary outcome assessor is different from the treating therapist; or acceptance by FDA of a functionally unblinded design with appropriate statistical sensitivity analyses. Which approach Lykos pursues in its remediation plan will define the shape of MDMA PTSD trials for the next phase of research.

In parallel, the psilocybin-for-PTSD research agenda has accelerated. While psilocybin-for-PTSD is earlier-stage than MDMA-AT — psilocybin is primarily validated in major depressive disorder (through breakthrough therapy designation) and existential distress in terminal illness — its therapeutic model (supported psilocybin sessions with psychotherapy integration) is mechanistically adjacent to MDMA-AT, and the communities of researchers, therapists, and funders overlap substantially. Moral injury-specific psilocybin trials in combat veterans are particularly active: the distinct phenomenology of moral distress (guilt, self-condemnation, loss of meaning) may be more accessible to psilocybin's ego-dissolution and perspective-shifting effects than to MDMA's empathogen properties.

The stellate ganglion block story is developing along a completely different axis: it is a procedural intervention, not a pharmacological one, and it does not carry the Schedule I regulatory burden that defines the clinical development pathway for MDMA and psilocybin. If the ongoing Phase 2/3 trials generate sufficiently consistent data for the bilateral cervical sympathetic block protocol, SGB could reach mainstream clinical practice in the VA system without requiring a new drug approval — through clinical guidelines and coverage decisions rather than NDA review. This is why the SGB trial registrations are worth monitoring even if they generate less press attention than the MDMA trials: their path to clinical implementation is shorter and less regulatory-dependent.

For organizations tracking the PTSD pipeline, the monitoring priority hierarchy in 2026 is: (1) Lykos' protocol amendment and resubmission timeline for MDMA-AT, (2) new psilocybin PTSD trial registrations and Phase 2 enrollment openings, (3) SGB Phase 3 enrollment milestones in veteran populations, (4) ketamine acute PTSD trial completions and publication, and (5) the emerging VA-funded research on family involvement and integrated care models that may represent the near-term scalable implementation pathway independent of novel pharmacology.

Who uses PTSD trial monitoring

VA and DoD mental health researchers

The Department of Veterans Affairs and Department of Defense fund a substantial proportion of the PTSD clinical trials portfolio — both pharmacological and psychotherapeutic. VA and DoD researchers monitor ClinicalTrials.gov to avoid duplication in funded research, to identify collaboration opportunities across VA centers and academic affiliates, and to track the private-sector (Lykos, ketamine clinic companies) pipeline alongside the government-funded research agenda. DataLookout's sponsor filter, set to include VA, DoD, and NIMH-sponsored studies alongside industry-sponsored ones, gives VA researchers a complete daily view of the PTSD trial landscape without manually running multiple searches.

PTSD-focused nonprofits and research funders

Cohen Veterans Bioscience, the Headstrong Project, Give an Hour, MAPS (Multidisciplinary Association for Psychedelic Studies), and similar organizations monitor the PTSD trial pipeline for research they fund, advocacy they conduct, and programs they refer their communities to. Cohen Veterans Bioscience specifically funds translational research (biomarkers, genomics, neuroimaging) aimed at precision medicine approaches to PTSD — and monitoring the clinical trial landscape helps identify where biomarker-informed patient stratification is being implemented in Phase 2/3 trials. MAPS monitors MDMA-AT trial activity globally as the organization that conducted the original MAPP trials and continues to support the therapeutic model's development.

CNS investors and psychedelic-assisted therapy companies

The investment landscape for psychedelic-assisted therapy remains active despite the MDMA CRL setback. COMPASS Pathways (psilocybin for treatment-resistant depression), MindMed, atai Life Sciences, and several others are developing psychedelic-adjacent programs. Investors in this space use DataLookout to track the PTSD-specific trial activity as a leading indicator of where the regulatory science is heading — because the endpoint, trial design, and blinding methodology questions raised in the MDMA CRL apply equally to future psilocybin and other psychedelic NDA submissions. Understanding what FDA will require based on Lykos' remediation path has direct implications for every psychedelic company's development timeline and capital requirements.

Psychedelic-assisted therapy practitioners and training programs

The clinical training infrastructure for psychedelic-assisted therapy — therapist certification programs, retreat centers operating legally in Oregon and Colorado, and international academic training programs — monitors the PTSD trial pipeline to understand which protocols are being validated in clinical research and how the regulatory landscape is evolving. Therapists who will eventually deliver MDMA-AT or psilocybin-AT need to know which manualized protocols are being tested in trials, because those protocols will likely form the basis for any eventual FDA-required therapist training program under a REMS.

How DataLookout works

DataLookout connects directly to the ClinicalTrials.gov API and checks for new and updated studies every morning. You specify the condition keywords (PTSD, moral injury, acute stress disorder) and intervention keywords (MDMA, psilocybin, ketamine, stellate ganglion block) you want to track, choose your sponsor type and phase filters, and we deliver a clean daily or weekly digest to your inbox. No login portal to manage. No manual searches. Reply to any digest email to update your profile at any time.

Pricing

Free — $0 forever: 1 disease tracker, weekly digest, ClinicalTrials.gov monitoring. No credit card required.

Starter — $49/month: 5 disease/keyword profiles, daily digest, all phase and sponsor filters. Best for individual analysts.

Pro — $149/month: Unlimited profiles, daily digest, priority support. Best for BD and CI teams.